Study Links Four Proteins To Esophageal Cancer


PITTSBURGH (MCT) — A study has identified four proteins associated with the onset of esophageal cancer, the precursor to developing a blood test for early detection and better treatment of a particularly lethal disease.

The findings — by doctors at Allegheny Health Network, the University of Pittsburgh, Roswell Park Cancer Institute in Buffalo, N.Y., and an Amsterdam medical center — were published online Tuesday by the journal Cancer.

The federally supported study occurred over four years.

“Esophageal cancer patients often have few options available to fight this disease, and five-year survival rates are extremely low at about 15 percent,” Blair Jobe, director of Allegheny Health Network’s Esophageal and Thoracic Institute and the study’s lead researcher, said in a statement.

According to the National Cancer Institute, 18,170 cases will be diagnosed this year, and 15,450 people who have the disease will die. According to the new study, the incidence of esophageal cancer is up 600 percent since the 1970s.

–Joe Smydo
Pittsburgh Post-Gazette


(c)2014 Pittsburgh Post-Gazette

Visit the Pittsburgh Post-Gazette at

Distributed by MCT Information Services.


Operated jointly by the McClatchy Company and Tribune Company, MCT serves more than 1,200 media clients, online information services and information resellers across the globe. With 600-plus contributors worldwide, MCT has an exceptional variety of sources, providing detailed analyses, opinions and perspectives.

Join the Discussion

Comment Policy: We encourage an open discussion with a wide range of viewpoints, even extreme ones, but we will not tolerate racism, profanity or slanderous comments toward the author(s) or comment participants. Make your case passionately, but civilly. Please don't stoop to name calling. We use filters for spam protection. If your comment does not appear, it is likely because it violates the above policy or contains links or language typical of spam. We reserve the right to remove comments at our discretion.